A non-profit committee of health and safety advisers to the Centers for Disease Control and Prevention approved three new booster vaccines for US adults on Friday as part of the CDC’s seasonal flu vaccine recommendations.
Beginning in December, the recommendations will allow doctors to include two new vaccines for the influenza vaccine: ID137 and Novartis’s Fluzone High Intensity Flu Vaccine (FLUVELTA).
Recommendations from the Vaccine Adverse Event Reporting System (VAERS) will also allow patients to access additional information to treat specific complaints caused by influenza or any other vaccine. For example, VAERS provides access to information about these types of reports for patients who have experienced a “slight fever, nasal congestion, mild cough, low grade fever, chills, sore throat, headache, muscle aches and fatigue in the three days before and after vaccination.”
VAERS is a voluntary reporting system and is run by the Center for Disease Control and Prevention.
The Advisory Committee on Immunization Practices also recommended in the past few years that Medicare and Medicaid pay for the flu vaccines (including the two new booster vaccines), citing evidence from other health care settings that encouraged coverage.